Another Phase-II clinical trial (ChiCTR2000029638) was conducted on moderate to severe COVID-19 patients to evaluate the safety and efficacy of Recombinant Super-Compound Interferon (rSIFN-co) versus traditional nebulized IFNα-2b, alongside standard antivirals (LPV/r or Umifenovir) (145). This evidence concerns the gene IFNA2 and COVID-19.